Walk down any skincare aisle right now and you will trip over the word "peptide" before you find a product that does not use it. Copper peptide. Signal peptide. Neuropeptide. Multi-peptide. The word has become shorthand for "this works," which is a problem, because peptide is a category, not a result. Some peptides have a real clinical paper trail. Others are riding on the reputation of the ones that do.
The copper peptide everyone is suddenly quoting
GHK-Cu, the copper peptide that shows up on ingredient lists as "copper tripeptide-1," is not new. It has been studied for more than four decades, which makes it one of the longest-running research threads in cosmetic dermatology. What is new is the volume of product built around it, from The Ordinary's Multi-Peptide + Copper Peptides 1% Serum to a wave of smaller brands leaning entirely on the copper story. The peer-reviewed data covers collagen synthesis, gene expression, wound healing, and skin laxity, and clinical trials have reported wrinkle and scar improvements in the 25 to 35 percent range. Those numbers sound decisive. They are not, because the trials behind them tend to run small and short, which is a polite way of saying the sample sizes and timelines would not survive a rigorous meta-analysis.
There is also a regulatory fact worth sitting with: GHK-Cu has no FDA approval for any medical indication, which puts every copper peptide serum on the shelf squarely in cosmetic, off-label territory. Dermatologists who take the ingredient seriously tend to describe it the same way, as a supporting player layered into a routine that already includes retinoids or in-office treatment, not a replacement for either.
The one with the actual paper trail
If one peptide in this whole category has earned its shelf space, it is palmitoyl pentapeptide-4, sold under the brand name Matrixyl. It is the most studied cosmetic peptide on the market, with more than ten published randomized controlled trials behind it. The mechanism is specific: the peptide mimics matrikines, the collagen fragments that signal fibroblasts to start repair work, and it does this by binding receptors on the fibroblast surface and activating the MAPK/ERK signaling pathway. That pathway upregulates collagen I, collagen III, and elastin. In vitro studies on skin explants have shown 100 to 200 percent increases in collagen I synthesis, and a 2005 placebo-controlled trial found an 18 percent reduction in wrinkle depth and a 37 percent reduction in fold thickness after 28 days of twice-daily use at 0.005% concentration.
A 2023 double-blind trial went further, putting palmitoyl pentapeptide-4 head-to-head against acetylhexapeptide-3, better known as Argireline, in 21 women over eight weeks, measuring crow's feet specifically. Matrixyl outperformed argireline on most of the measured skin parameters. That is a rare thing in this category: a direct comparison, not two separate marketing claims sitting next to each other on a shelf.
The Botox-adjacent ones, and where the claims get loose
Argireline, SNAP-8, and Syn-Ake work through an entirely different mechanism than Matrixyl or copper peptides. They are neurotransmitter-inhibiting peptides, marketed as blocking the nerve signals that trigger the muscle contractions behind expression lines, the same target Botox hits, just delivered topically instead of injected. That is a meaningfully smaller claim than collagen stimulation, and it should be marketed that way. Instead, serum copy routinely borrows Botox's reputation wholesale. One depology-style claim circulating this year states a formula reduces wrinkle depth by up to 63 percent in 28 days and is roughly 30 percent more potent than standard Argireline. Numbers like that deserve the same scrutiny as any other cosmetic claim: ask what the comparator was, how the depth was measured, and whether the study was independent.
Peptides work slowly, cumulatively, and only when the formulation gets them past the skin barrier intact. That is not a disclaimer. That is the entire category, and any serum copy that skips it is selling you the word instead of the ingredient.
None of this makes peptides worthless. It makes them a category that rewards reading the actual study behind the claim instead of the claim itself. A few reference points worth keeping straight:
- GHK-Cu (copper peptide): decades of research, genuinely interesting mechanism, but no FDA approval and small trial sizes. Treat as a support ingredient, not a headline treatment.
- Palmitoyl pentapeptide-4 (Matrixyl): the best-documented peptide in cosmetics, with direct head-to-head data against argireline-type peptides. Look for it specifically by name, not just "peptide complex."
- Argireline, SNAP-8, Syn-Ake: a narrower, muscle-relaxing mechanism that is real but frequently oversold with Botox comparisons that outrun the evidence.
Products built around named, dosed peptides, like The Ordinary's copper peptide serum or Rhode's peptide lip treatment, at least give you something to research. Vague "peptide complex" formulations that will not name a single peptide are the ones to treat with real suspicion. And because these ingredients interact with skin barrier function, wound healing, and in some formulations retinoid or acid actives, anyone dealing with sensitive skin, a skin condition, or a prescription topical routine should talk to a dermatologist before layering a new peptide serum on top of what they are already using. The science behind the best-studied peptides is real. That does not mean every bottle wearing the word has earned it.
